Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 473 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Paranasal Sinus Diseases Clear all
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment of Orthostatic Intolerance

NCT00262470
View directory record Official record
Conditions
Tachycardia, Chronic Orthostatic Intolerance
Interventions
Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
Drug · Other · Dietary Supplement + 3 more
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Implant-Abutment Interface Design on Bone and Soft Tissue Levels Around Implants Placed Using Different Transcrestal Sinus Floor Elevation

NCT02953392
View directory record Official record
Conditions
Tooth Loss
Interventions
Anorganic Bovine Bone Graft Material, Collagen Membrane, Shelta Platform Switching Premium Implants, Shelta Platform Matching Premium Implants
Device
Lead sponsor
NYU College of Dentistry
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 25, 2026, 4:14 AM EDT
Terminated Phase 3 Interventional Results available

Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)

NCT05545072
View directory record Official record
Conditions
Allergic Fungal Rhinosinusitis
Interventions
Dupilumab, Placebo, Intranasal Corticosteroid Sprays (INCS)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 25, 2026, 4:14 AM EDT
Completed No phase listed Observational

BREATHE Long-Term Follow-Up Study

NCT01319305
View directory record Official record
Conditions
Chronic Sinus Disease
Interventions
FinESS Sinus Treatment
Device
Lead sponsor
Entellus Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Saint Cloud, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Early Phase 1 Interventional

Sinopsys Lacrimal Stent Indicated for Sinus Irrigation

NCT02297243
View directory record Official record
Conditions
Ethmoid Sinusitis
Interventions
Sinopsys Lacrimal Stent
Device
Lead sponsor
Sinopsys Surgical
Industry
Eligibility
22 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Stanford, California • Greeley, Colorado • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 4 Interventional Results available

Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking

NCT00666978
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
smoking cessation intervention, bupropion hydrochloride, gene expression analysis, polymerase chain reaction, counseling intervention, educational intervention, psychosocial assessment and care
Behavioral · Drug · Genetic + 2 more
Lead sponsor
Lisa Sanderson Cox, PhD
Other
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

NCT01256385
View directory record Official record
Conditions
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Squamous Cell Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Verrucous Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Verrucous Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Oral Cavity Verrucous Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Verrucous Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Oral Cavity Verrucous Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
Interventions
Cetuximab, Laboratory Biomarker Analysis, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
23
States / cities
Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Results available

Safety and Performance of the SinuSys Dilation System for Dilation of the Maxillary Sinus Ostium

NCT01623050
View directory record Official record
Conditions
Sinusitis
Interventions
SinuSys Dilation System
Device
Lead sponsor
SinuSys Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Tucson, Arizona • Palo Alto, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors

NCT00978081
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous Condition
Interventions
aminolevulinic acid hydrochloride
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

NCT03682965
View directory record Official record
Conditions
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
Interventions
Intra-lymphatic allergenic extract, Intra-lymphatic placebo
Biological
Lead sponsor
Christopher Thompson, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Austin, Texas • Grapevine, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis

NCT00416182
View directory record Official record
Conditions
Sinusitis, Cystic Fibrosis
Interventions
Pulmozyme (dornase alfa), Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
5 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Sep 25, 2026, 4:14 AM EDT
Terminated Phase 1 Interventional

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

NCT01249443
View directory record Official record
Conditions
HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Anal Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vorinostat, diagnostic laboratory biomarker analysis, pharmacological study, carboplatin, paclitaxel
Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 25, 2026, 4:14 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Mom Power With High-Adversity Mothers and Children

NCT04241913
View directory record Official record
Conditions
Self-regulation, Respiratory Sinus Arrhythmia
Interventions
Mom Power Intervention
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

NCT00458978
View directory record Official record
Conditions
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Squamous Cell Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Laryngeal Squamous Cell Carcinoma, Stage IV Laryngeal Verrucous Carcinoma, Stage IV Lip and Oral Cavity Squamous Cell Carcinoma, Stage IV Major Salivary Gland Carcinoma, Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IV Oral Cavity Verrucous Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma, Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
Interventions
Cediranib Maleate, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 25, 2026, 4:14 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

In Vivo Imaging of the Olfactory Epithelium Using Confocal Laser Endomicroscopy

NCT07546617
View directory record Official record
Conditions
Endonasal Surgery, Endoscopic Sinus Surgery, Olfactory Dysfunction
Interventions
CONVIVO system, Fluorescein injection, USP 10%
Device · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 4 Interventional

A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation

NCT00540787
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Radiofrequency ablation, antiarrhythmic drugs, Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs, ThermoCool Radiofrequency Catheter
Device · Drug
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 25, 2026, 4:14 AM EDT
Terminated Not applicable Interventional

Effects of Endoscopic Sinus Surgery for Chronic Sinusitis on Asthma Control

NCT01066416
View directory record Official record
Conditions
Asthma, Chronic Sinusitis
Interventions
Endoscopic Sinus Surgery, medical therapy
Procedure · Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Not applicable Interventional Results available

The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery

NCT02562924
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyposis
Interventions
MEDIHONEY®, Budesonide, Normal saline sinus rinse, Prednisone, Endoscopic sinus surgery, nasal saline spray
Device · Drug · Procedure
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 4 Interventional

Phase 4 Study - Mucinex D as Adjunct Therapy

NCT00441246
View directory record Official record
Conditions
Acute Respiratory Infection, Bronchitis, Rhinosinusitis
Interventions
Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)
Drug
Lead sponsor
Adams Respiratory Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Carmichael, California • Torrance, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2008 · Synced Sep 25, 2026, 4:14 AM EDT
Completed No phase listed Observational

Surgery Checklist and Process Improvement Surrounding Endoscopic Sinus Surgery

NCT01499719
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
Checklist introduction / Pause
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

NCT01316757
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
cetuximab, paclitaxel, carboplatin, erlotinib hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Rochester, New York • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Sep 25, 2026, 4:14 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Dupixent Study for Alternate Administration

NCT06750471
View directory record Official record
Conditions
Nasal Polyps, Sinusitis, Chronic Disease
Interventions
Dupilumab
Biological
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 25, 2026, 4:14 AM EDT
Terminated Not applicable Interventional Results available

Effects of SinuSonic on Psychological and Physical Well-Being

NCT06268730
View directory record Official record
Conditions
Nasal Congestion and Inflammations, Sinus Congestion Chronic
Interventions
SinuSonic
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 25, 2026, 4:14 AM EDT
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults

NCT00643409
View directory record Official record
Conditions
Maxillary Sinusitis
Interventions
azithromycin SR (Zithromax; compound: CP-62,993), placebo, levofloxacin
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
59
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hueytown, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Sep 25, 2026, 4:14 AM EDT